A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia
Introduction
Metabolic syndrome (MetS) is a grouping of biochemical and physiological risk factors for cardiovascular disease (CVD), including abdominal obesity, dyslipidaemia, insulin resistance and elevated blood pressure (BP) (Cornier et al., 2008). These individual components of MetS are independent risk factors for CVD as well. The presence of MetS has also been associated with other comorbidities such as the prothrombotic state, nonalcoholic fatty liver disease, proinflammatory states and reproductive disorders (Cornier et al., 2008). The incidence of MetS is significantly higher in patients with schizophrenia than in the general population (De Hert et al., 2006). Indeed, CVD has been identified as one of the leading causes of mortality among patients with schizophrenia (Yu et al., 2013). There are several definitions of MetS, however the International Diabetes Federation Task Force recently proposed revised criteria in an attempt to unify the diagnosis of MetS internationally (Alberti et al., 2009). According to this revision, MetS can be diagnosed if any three of the five criteria described below are present:
- 1.
Elevated waist circumference, according to population- and country-specific definitions
- 2.
Elevated triglycerides (TG) (≥ 150 mg/dl or 1.7 mmol/l) or pharmacological treatment for elevated TG
- 3.
Reduced high-density lipoprotein cholesterol (HDL-C) (< 40 mg/dl or 1.03 mmol/l in males and < 50 mg/dl or 1.29 mmol/l in females) or pharmacological treatment for reduced HDL-C.
- 4.
Elevated blood pressure (BP) (systolic ≥ 130 mmHg, diastolic ≥ 85 mmHg) or pharmacological treatment for hypertension.
- 5.
Elevated fasting glucose (≥ 100 mg/dl or 5.6 mmol/l) or pharmacological treatment for hyperglycemia
The high prevalence of MetS in patients with schizophrenia has, in part, been attributed to unhealthy lifestyle, including poor diet and sedentary behavior and smoking (Ringen et al., 2014). However, in recent years, the severe metabolic side-effects of antipsychotics (APs) have also become more apparent (Fleischhacker et al., 2008, Casey et al., 2004, Leucht et al., 2007). In particular, second-generation APs (SGA), such as Olanzapine (OLZ) and Clozapine (CLZ) are associated with metabolic abnormalities (Rummel-Kluge et al., 2010). Treatment with these drugs has been found to cause weight gain (Gunes et al., 2009, Simpson et al., 2001) and increase blood lipid and glucose levels (Smith et al., 2008). Low-potency first-generation APs (FGAs), administered to first-episode psychosis (FEP) patients, have also been associated with increased body mass index (BMI) and lipid profiles over time (Chiliza et al., 2015). While the use of APs is associated with weight gain (Bak et al., 2014), the high incidence of MetS in patients with schizophrenia cannot be solely attributed to the APs. For instance, in the twentieth century, prior to the development of AP medications, Henry Maudsley noticed an association between diabetes and schizophrenia (Maudsley, 1979). Since that time, studies have also demonstrated that AP-naïve patients exhibit increased visceral fat distribution, impaired glucose tolerance and increased insulin resistance compared with normal controls (Thakore et al., 2002, Venkatasubramanian et al., 2007, Fernandez-Egea et al., 2008). Furthermore, some studies have noted an increased prevalence of type II diabetes in the parents of individuals with non-affective psychosis and increased glucose intolerance in the siblings of patients with schizophrenia (Fernandez-Egea et al., 2009a, b), suggesting that heritable factors (genetic or epigenetic) may contribute to this increased prevalence.
A recent Danish study found that schizophrenia was associated with a type II diabetes risk allele located in the transcription factor 7-like 2 (T-cell specific, HMG-box) (TCF7L2) gene (Hansen et al., 2011), which suggests that diabetes and schizophrenia may share familial risk factors or a common genetic predisposition (Papanastasiou, 2013). Furthermore, studies have suggested that the presence of polymorphisms in certain candidate genes may result in increased susceptibility to the development of MetS with AP treatment (Gunes et al., 2009). It has, therefore, been hypothesized that the risk of developing MetS in patients with schizophrenia is influenced by an interaction between genetic polymorphisms, lifestyle factors and APs (Smith et al., 2008). The identification of polymorphisms that play a role in the development of MetS in patients with schizophrenia could facilitate the development of optimal treatment strategies (Smith et al., 2008). This systematic review focuses on 34 studies that have investigated genetic polymorphisms which may be associated with more severe metabolic derangements in these patients (Table 1, Supplementary Table S1). However, differences across studies make it difficult to ascertain the extent to which genetic polymorphisms play a role. Sources of heterogeneity include AP prescription and MetS diagnostic parameters. Sample size, ethnicity, gender, comorbidity, antidepressant use, age of onset, lifestyle and substance abuse are additional factors that may influence the role played by genetic polymorphisms in the development of MetS.
In this study, we systematically review and compare association studies of genes implicated in the development of MetS in patients with schizophrenia, in an effort to identify common variants that may contribute to the high comorbidity between MetS and schizophrenia, and which could, potentially, identify patients at increased risk for developing MetS.
Section snippets
Search strategy
Independent searches were performed during June 2014–June 2015 in three databases, namely PubMed, Web of Science and Scopus. The following search terms were used: (‘schizophrenia’ or ‘schizophrenic’ or ‘psychosis’ or ‘schizophrenia spectrum’ or ‘schizoaffective’ OR ‘delusional’) and (‘genes’ or ‘genetic’ or ‘genetic polymorphism’ or ‘gene variant’ or ‘single nucleotide polymorphism’) and (‘metabolic syndrome’ or ‘MetS’ or ‘cardiometabolic syndrome’). No filters were included.
Inclusion criteria
- •
Studies published
Included studies
Database searches resulted in a total of 1905 records. Of these, 1506 duplicate records and seventeen records that were not in English were excluded. The remaining 382 records were screened and 341 records were excluded on the basis that these were either animal studies, meta-analyses or systematic reviews, conference papers, or studies that did not investigate genetic polymorphisms, MetS or schizophrenia. Forty-one full-text articles were reviewed and seven studies were excluded as they did
Discussion
This systematic review compared studies that investigated the association between genetic variants and the development of MetS in patients with schizophrenia, with the aim of identifying common variants in patients at particular risk for developing MetS. Replication across multiple studies and longitudinal study designs provided more robust evidence for variants that are truly associated with MetS (or features of MetS) in patients with schizophrenia (e.g., LEP, LEPR, HTR2C, FTO and MTHFR). For
Conclusions and future recommendations
Future studies should include larger samples, healthy control groups, FEP drug-naïve patients and longitudinal study designs with longer follow-up periods. Also, in view of the differential adipogenic and dysmetabolic effects of APs, treatment should be standardized. It is possible that certain metabolic abnormalities might only manifest after chronic and long-term (several years) exposure to APs, as shown by Reynolds et al. (2013). Where possible, information on other factors associated with
Role of funding source
No funding body agreements. See list of funders under acknowledgements.
Contributors
SS designed the study and SMM and SK performed the literature searches, collected and analyzed the data and constructed the draft manuscript. SS, SMJH, LA, RAE, SB, LvdH and LW assisted with writing and editing of manuscript. All authors contributed to and have approved the final manuscript.
Conflict of interest
SMM, SK, SMJH, SB, LvdH, LW and LA declare no conflict of interests. RAE has received honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, Lilly, Lundbeck, Organon, Pfizer, Servier, Otsuka and Wyeth for participating in advisory boards and speaking at educational meetings, and has received research funding from Janssen, Lundbeck and AstraZeneca. SS has received pharmaceutical sponsorship from Pfizer, Astra Zeneca, Servier, and Dr. Reddy's, speaker's honoraria from Pfizer and Lundbeck, and
Acknowledgments
This work is supported by the Medical Research Council of South Africa (MRC Flagship Grant RFA-UFSP-01-2013) and the South African Research Chair in Posttraumatic Stress Disorder (SARChI UID 64811), funded by the Department of Science and Technology and the National Research Foundation.
References (173)
- et al.
Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls
Mol. Genet. Metab.
(2010) - et al.
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics
Schizophr. Res.
(2011) - et al.
A review of central 5-HT receptors and theirfunction
Neuropharmacology
(1999) - et al.
Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma
Biochem. Biophys. Res. Commun.
(1997) - et al.
No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response
Neurosci. Lett.
(2000) S-adenosylmethionine: a new intermediate formed enzymatically from I-methionine and adenosine triphosphate
J. Biol. Chem.
(1953)- et al.
Network interactions in schizophrenia — therapeutic implications
Brain Res. Interactive
(2000) - et al.
Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis
Biol. Psychiatry
(2003) - et al.
A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
Mol. Cell
(2001) - et al.
Gender differences in the effects of peroxisome proliferator-activated receptor gamma2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2011)
Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic
Eur. Psychiatr.
Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population
Biol. Psychiatry Investig.
Influence of catechol-O-methyltransferase Val158Met polymorphism on startle response in the presence of high estradiol levels
Eur. Neuropsychopharmacol.
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants
Schizophr. Res.
PPARs and the complex journey to obesity
Nat. Med.
The genetics of obesity: FTO leads the way
Trends Genet.
Parental history of type 2 diabetes in patients with nonaffective psychosis
Schizophr. Res.
Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin
Schizophr. Res.
Pro12Ala polymorphism of the PPAR-γ2 gene, metabolic syndrome and response to metformin in clozapine-treated patients
Schizophr. Res.
Common INSIG2 polymorphisms are associated with age-related changes in body size and high-density lipoprotein cholesterol from young adulthood to middle age
Metabolism
At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia
Biol. Psychiatry
Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites
Brain Res.
The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries
Eur. J. Pharmacol.
Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes
Schizophr. Res.
Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C)
Genomics
Association study of serotonin 2A receptor (5-HT2A) gene with schizophrenia and suicidal behavior using systematic meta-analysis
Biochem. Biophys. Res. Commun.
New functions of cholesterol binding proteins
Mol. Cell. Endocrinol.
Expression of noradrenergic alpha1, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
Circulation
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database
Nat. Genet.
Non-replication of genome-wide based associations between common variants in INSIG2 and PFKP and obesity in studies of 18,014 Danes
PLoS One
Almost all antipsychotics result in weight gain: a meta-analysis
PLoS One
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle
J. Clin. Psychiatry
Mild encephalitis underlying psychiatric disorders — a reconsideration and hypothesis exemplified on Borna disease
Neurol. Psychiatry Brain Res.
Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations
Hum. Mol. Genet.
Association between C-reactive protein and adiposity in women
J. Clin. Endocrinol. Metab.
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
J. Clin. Psychiatry
Gender differences in the effects of peroxisome proliferator-activated receptor γ2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder
Prog. Neuropsychopharmacol. Biol. Psychiatry
FTO obesity variant circuitry and adipocyte browning in humans
N. Engl. J. Med.
The metabolic syndrome
Endocr. Rev.
Pharmacogenetics of antipsychotic-induced weight gain
Psychopharmacology
Emerging roles of PPARs in inflammation and immunity
Nat. Rev. Immunol.
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study
Clin. Pract. Epidemiol. Ment. Health
The cortical serotonin 2A receptor and the pathology of schizophrenia: a likely accomplice
J. Neurochem.
A Pro12Ala substitution in PPARbig gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
Nat. Genet.
A tagging SNP in INSIG2 is associated with obesity-related phenotypes among Samoans
BMC Med. Genet.
Peroxisome proliferator-activated receptors: nuclear control of metabolism
Endocr. Rev.
Variation in FTO contributes to childhood obesity and severe adult obesity
Nat. Genet.
The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects
Rom. J. Intern. Med.
Cited by (76)
Deep retinal layer microvasculature alterations in schizophrenia
2024, Biomarkers in NeuropsychiatryIdentification of genetic loci that overlap between schizophrenia and metabolic syndrome
2022, Psychiatry ResearchCitation Excerpt :Several genes, such as LEP, LEPR, HTR2C, FTO, BDNF, and MTHFR, have shown strong evidence for the association with MetS in patients with SCZ. ( Malan-Müller et al., 2016; Kalejahi et al., 2021) Furthermore, a cross-trait genome-wide association study (GWAS) identified shared common risk variants of SCZ and MetS traits (dyslipidemia, waist-to-hip ratio, blood pressure [BP], and body mass index [BMI]) (Andreassen et al., 2013). However, only a few genetic risk variants shared between SCZ and MetS have been identified.